Since our previous study had shown that CLF erodes quiescent stem-cell populations (CD34+CD38-, CFSE-bright) in drug-resistant CML patients (10), we also showed that CLF kills quiescent/dormant cells, ALDH+ cells, and side populations (SPs), collectively referred to as putative stem-like cells in myeloma, with treatment-refractory phenotypes (16–19). The gene discussed is CD34; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.